US 12,435,150 B2
Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
Pascal Espie, Saint Louis (FR); Christian Loesche, Hegenheim (FR); Lukas Roth, Riehen (CH); James Rush, Thalwil (CH); and Grazyna Wieczorek, Schönenbuch (CH)
Assigned to NOVARTIS AG, Basel (CH)
Appl. No. 17/422,075
Filed by NOVARTIS AG, Basel (CH)
PCT Filed Jan. 9, 2020, PCT No. PCT/IB2020/050132
§ 371(c)(1), (2) Date Jul. 9, 2021,
PCT Pub. No. WO2020/144605, PCT Pub. Date Jul. 16, 2020.
Claims priority of application No. 19151461 (EP), filed on Jan. 11, 2019.
Prior Publication US 2022/0098315 A1, Mar. 31, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61P 17/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61P 17/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 4 Claims
 
1. A method of treating hidradenitis suppurativa in a patient in need thereof, the method comprising administering to the patient an effective amount of a CD40 antagonist, wherein the CD40 antagonist is CFZ533 and comprises a heavy chain amino acid sequence of SEQ ID NO: 9 and a light chain amino acid sequence of SEQ ID NO: 10, and wherein the effective amount is administered with a weekly loading dose of about 600 mg active ingredient, and the effective amount is subsequently administered with an every other week maintenance dose of about 600 mg active ingredient, and the route of administration is subcutaneous.